Pancreatic Cancer Research

ResearcherUniversity of MiamiActive in the last 2 years

Nagaraj S. Nagathihalli

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2373-3293; OpenAlex author ID A5034445995; NIH RePORTER profile ID 10727648. Sources: OpenAlex.

Their work

Papers
24 (first author 0, last author 10)
Trials
0
Grants
3
Labs led
1
Collaborators
36
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 1 grant · 2018: 2 papers · 2019: 3 papers · 2020: 1 paper · 2021: 3 papers, 1 grant · 2022: 3 papers · 2023: 2 papers · 2024: 1 paper · 2025: 4 papers · 2026: 1 grant

Papers 24

  1. Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invigorate antitumor immunity in pancreatic c… Co-author DOI 10.1007/s00262-025-04096-y↗
  2. CREB Drives Acinar to Ductal Cells Reprogramming and Promotes Pancreatic Cancer Progression in Preclinical Models of Alcoholic Pancreatitis. Last author DOI 10.1016/j.jcmgh.2025.101606↗
  3. Editor's Note: Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-1304↗
  4. Targeting CREB remodels the immune microenvironment to enhance immunotherapy responses in pancreatic cancer Last author DOI 10.64898/2025.12.04.691935↗
  5. Tumor Cell-Intrinsic p38 MAPK Signaling Promotes IL1α-Mediated Stromal Inflammation and Therapeutic Resistance in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-23-1200↗
  6. Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-22-1046↗
  7. Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer. Last author DOI 10.1158/2767-9764.crc-22-0329↗
  8. Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer. Co-author DOI 10.1038/s41388-022-02368-w↗
  9. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overco… Co-author DOI 10.1053/j.gastro.2022.07.076↗
  10. Emerging Role of CREB in Epithelial to Mesenchymal Plasticity of Pancreatic Cancer. Last author DOI 10.3389/fonc.2022.925687↗
  11. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1535-7163.mct-19-1043↗
  12. Targeting Tumor-Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-21-0083↗
  13. Targeting PI3K Pathway in Pancreatic Ductal Adenocarcinoma: Rationale and Progress. Last author DOI 10.3390/cancers13174434↗
  14. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer. Last author DOI 10.1158/1541-7786.mcr-19-0741↗
  15. Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer. Last author DOI 10.1158/1535-7163.mct-18-0464↗
  16. Src kinase inhibition restores E-cadherin expression in dasatinib-sensitive pancreatic cancer cells. Last author DOI 10.18632/oncotarget.26621↗
  17. New mechanistic insights into modifiable risk factors that promote pancreatic cancer. Last author DOI 10.18632/oncotarget.26813↗
  18. Tobacco Carcinogen-Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-18-0579↗
  19. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-0634↗
  20. Optical Imaging of Drug-Induced Metabolism Changes in Murine and Human Pancreatic Cancer Organoids Reveals Heterogeneous Drug Response. Co-author DOI 10.1097/mpa.0000000000000543↗
  21. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model … Co-author DOI 10.1053/j.gastro.2015.07.058↗
  22. Emerging targets in pancreatic cancer: epithelial-mesenchymal transition and cancer stem cells. Co-author DOI 10.2147/ott.s34670↗
  23. Src-mediated regulation of E-cadherin and EMT in pancreatic cancer. Co-author DOI 10.2741/4037↗
  24. RAD51 as a potential biomarker and therapeutic target for pancreatic cancer. Co-author DOI 10.1016/j.bbcan.2011.07.004↗

Grants 3

  1. Impact of CREB-driven mechanism in shaping the tumor-immune landscape R01CA262526↗
  2. Combining Immunotherapy with Urolithin A to Improve Pancreatic Cancer Survival R03CA249401↗
  3. Targeting cytokine mediated CREB activation in pancreatic cancer R21CA209536↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nipun B. Merchant · 18 shared papers, 2015–2025 · strength 2.35
  2. Siddharth Mehra · 13 shared papers, 2020–2025 · strength 2.13
  3. Austin R. Dosch · 14 shared papers, 2018–2025 · strength 1.84
  4. Samara P. Singh · 8 shared papers, 2021–2025 · strength 1.28
  5. Iago De Castro Silva · 8 shared papers, 2021–2025 · strength 1.23
  6. Supriya Srinivasan · 9 shared papers, 2018–2025 · strength 1.19
  7. Haleh Amirian · 5 shared papers, 2023–2025 · strength 0.91
  8. Michael Nathan VanSaun · 7 shared papers, 2018–2025 · strength 0.90
  9. Jason A. Castellanos · 9 shared papers, 2013–2025 · strength 0.88
  10. Jashodeep Datta · 4 shared papers, 2021–2025 · strength 0.72
  11. Jashodeep Datta · 5 shared papers, 2022–2024 · strength 0.71
  12. Nilesh Deshpande · 4 shared papers, 2021–2025 · strength 0.68
  13. Chanjuan Shi · 5 shared papers, 2015–2025 · strength 0.54
  14. Anna Bianchi · 3 shared papers, 2023–2025 · strength 0.50
  15. Christine Isabelle Rafie · 3 shared papers, 2022–2025 · strength 0.46
  16. Tulasigeri M. Totiger · 3 shared papers, 2018–2025 · strength 0.35
  17. Ifeanyichukwu Chinedu Ogobuiro · 2 shared papers, 2023–2025 · strength 0.34
  18. Xi Chen · 1 shared paper, 2025 · strength 0.25
  19. Peter J. Hosein · 2 shared papers, 2022 · strength 0.24
  20. Brent A. Willobee · 2 shared papers, 2020–2021 · strength 0.23
  21. Kathleen E. DelGiorno · 1 shared paper, 2025 · strength 0.19
  22. Oliver Gene McDonald · 1 shared paper, 2025 · strength 0.19
  23. Vineet Kumar Gupta · 1 shared paper, 2025 · strength 0.19
  24. Eli Gilboa · 1 shared paper, 2023 · strength 0.16
  25. William L. Hwang · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.